Histone deacetylase (HDAC) inhibitors have shown promise in treating various forms of
cancer. However, many HDAC inhibitors from diverse structural classes have been …

Acetylation belongs to a class of post-translational modification (PTM) processes that
epigenetically regulate gene expression and gene transcriptional activity. Reversible …

Histone deacetylases (HDACs) remove acetyl groups from the tails of lysine residues of
histone protein in nuclear chromatin and also from acetylated sites in non-histone proteins …

Histone deacetylases (HDACs) regulate the acetylation of a variety of histone and
nonhistone proteins, controlling the transcription and regulation of genes involved in cell …

Histone deacetylase inhibitors (HDACi) are a promising new class of chemotherapeutic drug
currently in early phase clinical trials. A large number of structurally diverse HDACi have …

Purpose Epigenetic processes are implicated in cancer causation and progression. The
acetylation status of histones regulates access of transcription factors to DNA and influences …

Epigenic modifications, mainly DNA methylation and acetylation, are recognized as the main
mechanisms contributing to the malignant phenotype. Acetylation and deacetylation are …

Histone deacetylases (HDACs) and histone acetyltransferases (HATs) are enzymes that
catalyze the deacetylation and acetylation of lysine residues located in the NH2 terminal …

The role of histone deacetylases (HDAC) and the potential of these enzymes as therapeutic
targets for cancer, neurodegenerative diseases and a number of other disorders is an area …

Histone deacetylase inhibitors (HDACi) are in clinical trials against a variety of cancers.
Despite early successes, results against the more common solid tumors have been mixed …